Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

LY5625573 · VTX3232

Small molecule · developed by ELI LILLY &

Phase 1 Most advanced trial

LLY Developer

1 Registered trials

What is LY5625573?

LY5625573 (also known as VTX3232) is an orally administered tablet.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: VTX3232
Drug type: Small molecule
Therapy area: Cardiovascular
Developer: ELI LILLY & (LLY)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07867340	Phase 1	C-Reactive Protein	Not yet recruiting	LLY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

C-Reactive Protein

More from ELI LILLY &

Abemaciclib FDA approved Baricitinib FDA approved Donanemab FDA approved Dulaglutide FDA approved Imlunestrant FDA approved Lebrikizumab FDA approved Mirikizumab FDA approved Orforglipron FDA approved Pirtobrutinib FDA approved Selpercatinib FDA approved Tirzepatide FDA approved Brenipatide Phase 3

Sources

ClinicalTrials.gov NCT07867340

Updated Oct 11, 2026. Something wrong or missing? Report it on the LLY page.

Follow LLY, the company behind LY5625573

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z